The NIH SBIR/STTR Hiatus: Why There Are Zero Active Omnibus NOFOs in June 2026 — and What to Do Before September 8
June 3, 2026 · 7 min read
Claire Cummings
For the first time in more than a decade, the National Institutes of Health entered June with no active SBIR or STTR omnibus Notices of Funding Opportunity on the books. The 2024-2 series — PA-24-245 through PA-24-248, the four parent solicitations that have funded thousands of small businesses across NIH's twenty-seven institutes — expired without a successor in place. Applicants who logged into the NIH SEED portal in May expecting to start a Phase I proposal found a holding page and a forecasted reposting date of June 1, 2026. The next standard receipt date is September 8, 2026, pushed back from September 5 because the fifth falls on a Saturday and the following Monday is Labor Day.
A three-month omnibus gap is unprecedented in recent NIH SBIR history. The agency has previously absorbed reauthorization disruption, government shutdowns, and the SBIR program's 2022 statutory cliff without breaking the omnibus posting cadence. The fact that it broke now — and that the institute is using the gap to publish a substantially revised parent solicitation rather than a routine refresh — is the news. Two structural changes in the new omnibus deserve the attention of every small business that has ever competed for an NIH award, and most of all from teams sitting on translational work that has been stuck between Phase I and Phase II.
Why the omnibus is being reposted, not refreshed
The four expired parent announcements — PA-24-245 (SBIR R43/R44, clinical trial not allowed), PA-24-246 (SBIR clinical trial required), PA-24-247 (STTR R41/R42, clinical trial not allowed), and PA-24-248 (STTR clinical trial required) — were issued in mid-2024 under a set of policy assumptions that no longer hold. Three things have changed since.
First, the SBIR/STTR program was reauthorized in late 2025 with new requirements for foreign risk management, performance benchmarks, and the eligibility of multi-award winners. NIH has been working through the implementing guidance since the law passed.
Second, the OMB rewrite of 2 CFR Part 200 published on May 29 will be effective October 1, 2026 — meaning any award NIH issues from the September 8 receipt date forward will be governed by the new uniform guidance, including the pre-issuance political review by senior agency appointees and the broader termination-for-convenience authority. The parent solicitations need to reflect that.
Third, the FY26 NIH appropriations include the multi-year forward-funding pattern that has already absorbed roughly $2.2 billion of FY26 budget authority to honor prior-year award commitments. The omnibus posting needs to align award sizes and review priorities with the remaining new-money envelope, which is materially smaller than what the 2024-2 series assumed.
That combination — reauthorization-driven application changes, uniform guidance compliance, and a tighter new-award budget — explains why NIH is treating this as a reset rather than a refresh. Applicants should expect the new parent announcements to look meaningfully different. Award sizes, application section length limits, and human-subjects sections will all carry the fingerprints of the policy changes above.
The quiet headline — Direct-to-Phase II STTR is now available
The most under-discussed change in the new omnibus series is the addition of Direct-to-Phase II awards under the STTR program. The SBIR Direct-to-Phase II mechanism has existed since 2011 — it lets small businesses with documented Phase I-equivalent feasibility skip Phase I and apply directly for the larger Phase II envelope, currently up to $2 million over two years for most NIH institutes. STTR did not have an equivalent pathway. Teams whose feasibility work was done in collaboration with a university lab — the defining characteristic of STTR — had to start at Phase I no matter how mature the technology.
That changes with the new omnibus. Under the FY26 STTR parent announcement, small businesses can apply for Direct-to-Phase II STTR awards if they can document Phase I-equivalent feasibility — meaning published peer-reviewed work, preliminary in vivo data, or analogous validation evidence developed under non-NIH funding such as foundation grants, university discretionary funds, or company-funded research. The required research-institution partnership remains in force. The 30 percent minimum subaward to a research institution remains in force. The substantive change is the elimination of the Phase I gate for teams that can clear the feasibility documentation bar.
For university spin-outs, this is the most important NIH SBIR-related policy change in five years. The classic STTR friction point — a research institution has done the discovery work, a startup has been spun out around the IP, and the company now has to go back to NIH to fund a Phase I that re-validates what the lab already published — disappears. The new pathway compresses the time-to-Phase II from roughly three years (Phase I award timeline plus Phase II competition) to roughly fifteen months from application to award.
The feasibility documentation requirement will be the binding constraint. NIH study sections reviewing Direct-to-Phase II SBIR applications have historically been strict about what counts. Peer-reviewed publications carry the most weight. Conference proceedings carry less. Internal company data carries even less. Teams considering this pathway should audit their preliminary data this month and identify which results they can credibly cite as Phase I-equivalent. Where the evidence is thin, the right move is to submit a regular Phase I, not gamble on a Direct-to-Phase II that will get triaged.
What the new omnibus will likely require
Until the official reposting hits Grants.gov, applicants cannot know the final text. But the policy environment around the reposting tells us with high confidence what will change.
Foreign risk management certifications will expand. The 2025 SBIR reauthorization tightened restrictions on foreign affiliations, foreign ownership, and overseas R&D performance. Expect the new parent solicitations to require expanded SF-LLL-equivalent disclosures, named-individual conflict screening, and certifications about any foreign government talent program affiliations of senior personnel. Teams with international co-founders, university partners with overseas branch campuses, or contractors based outside the United States should map their disclosure exposure before drafting.
Indirect cost narratives will be scrutinized. The OMB rewrite explicitly pressures applicants toward lower indirect cost rates. Small businesses without a negotiated indirect cost rate agreement have historically defaulted to the 10 percent de minimis. The new uniform guidance preserves that option but layers a pre-issuance review on top — meaning a senior political appointee at NIH may flag any indirect rate above de minimis for additional justification. Plan the budget narrative around defending whatever rate you use.
Specific Aims pages will face heavier policy-alignment scrutiny. Under the new uniform guidance, applications will be reviewed for whether they "demonstrably advance the President's policy priorities." NIH study sections will still review for scientific merit, but the post-review political pre-issuance gate is new. Specific Aims that read as if written for a 2022 NIH funding climate will compete poorly against Specific Aims that connect to the administration's stated priorities in biomedical research — including domestic manufacturing of medical products, US-based clinical trial infrastructure, and anti-aging or longevity-adjacent research lines that the current administration has signaled support for.
What to do this week
Five concrete actions for any small business planning a Q3 2026 NIH SBIR or STTR submission:
- Pull every published or about-to-be-published paper from your team and university partners and inventory which results constitute Phase I-equivalent feasibility evidence. This is the single most important Direct-to-Phase II STTR preparation step. If you have a strong peer-reviewed in vivo result, you may be eligible for a $2 million two-year award you would otherwise have spent eighteen months competing for in two stages.
- Confirm your institutional alignment with the FY26 SBIR reauthorization's foreign risk requirements. Get written confirmation from your finance and HR teams that no senior personnel are participating in foreign government talent recruitment programs, and that no overseas R&D performance is planned for the project.
- Draft your indirect cost rate justification now. If you use a rate above de minimis, prepare a one-paragraph budget narrative defending it. Audit-ready documentation will matter more in FY26 than it did in FY24.
- Identify a transition partner. NIH SBIR awards increasingly favor applications with named commercialization partners — health systems, payers, or pharmaceutical partners. Lock the letter of support before the application is due.
- Calendar the September 8 receipt date with a four-week internal buffer. That means draft completion by August 11 and SRA review through August 25. The compressed window between omnibus posting and standard receipt date will pressure SRA offices everywhere — get in line early.
The NIH SBIR/STTR omnibus reset is the kind of administrative event that looks like a calendar hiccup from the outside and reshapes a sector's funding strategy from the inside. The Direct-to-Phase II STTR pathway will be the most consequential change for university-affiliated small businesses in years. Teams that move on the documentation work this month will own the September 8 cohort. Teams that wait for the official posting will find themselves writing under deadline pressure in a policy environment that has materially shifted under them.
Sources: